Director Laura Brege filed a Form 4 with the SEC on November 17, 2026, reporting the disposition of all directly held common stock, restricted stock units, and stock options in Pacira BioSciences, Inc. (NASDAQ:PCRX) following the completion of a cash merger with Viatris Inc.
Key Highlights
- Merger completed November 17, 2026: Pacira BioSciences was acquired by Viatris Inc. through Peach Purchaser Sub Inc. under a merger agreement dated October 8, 2026.
- Offer price of $36.50 per share: Each share of Pacira BioSciences common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest.
- 23,715 shares disposed: Brege disposed of 23,715 shares of common stock at $36.50 per share pursuant to the tender offer (transaction code U).
- 6,405 RSU shares canceled: Outstanding restricted stock unit awards were canceled and converted into the right to receive $36.50 per underlying share, net of applicable tax withholdings (transaction code D).
- Ten stock option grants canceled: All outstanding options, whether vested or unvested, were canceled; options with an exercise price at or above $36.50 received no consideration.
- Zero remaining beneficial ownership: Following all transactions, Brege holds 0 shares of Pacira BioSciences common stock directly.
Laura Brege's Holdings Extinguished in Pacira-Viatris Cash Merger
According to the filing, the transactions reported by director Laura Brege occurred on November 17, 2026, the effective time of the merger between Pacira BioSciences, Inc. and Peach Purchaser Sub Inc., a subsidiary of Viatris Inc. The merger agreement, dated October 8, 2026, provided that each outstanding share of Pacira BioSciences common stock would be converted into the right to receive $36.50 per share, described in the filing as "the Offer Price," net of applicable withholding taxes and without interest. Brege disposed of 23,715 shares under transaction code U, leaving an interim balance of 6,405 shares.
The remaining 6,405 shares, which the filing attributes to outstanding restricted stock unit awards, were then canceled at the effective time under transaction code D. The filing states that each RSU, "whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings." After this transaction, Brege's direct beneficial ownership of common stock was reduced to zero.
The filing also reports the cancellation of ten separate stock option grants with exercise prices ranging from $23.42 to $60.96 per share and expiration dates from June 15, 2026, through June 10, 2036. The filing notes that options with a per-share exercise price at or above the $36.50 offer price were "cancelled at the Effective Time with no consideration payable." Options with exercise prices below the offer price were converted into the right to receive cash equal to the spread between the offer price and the exercise price, multiplied by the number of shares subject to the option, subject to applicable tax withholdings. All ten option positions were reduced to zero following the reported transactions.
What Was Disclosed
Director Laura Brege reported the full disposition of her Pacira BioSciences common stock, RSU awards, and all ten stock option grants on November 17, 2026, as a result of the company's cash merger with Viatris Inc. at $36.50 per share. No beneficial ownership remains.




Please wait processing your request...